文献速递腹部介入技术与安全CT

使用机器学习预测中期肝细胞癌经动脉化疗栓塞术后进展至晚期

Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

这项多中心回顾性研究纳入2008年6月至2022年12月七家医院接受经动脉化疗栓塞术的中期肝细胞癌患者2333例,将34个术前临床和CT影像变量输入六种机器学习模型预测晚期进展。CatBoost模型预测性能最高,外部测试集AUC为0.93,优于五种现有分期系统,并能识别从术后全身治疗获益的高风险患者。

要点

  • CatBoost模型预测中期肝细胞癌经动脉化疗栓塞术后晚期进展的外部测试集AUC为0.93。
  • CatBoost模型的区分能力优于五种现有分期系统,所有P值均小于0.001。
  • 高风险组患者术后全身治疗改善无进展生存期和总生存期,低风险组未获益。

核心结论

  • CatBoost模型在预测中期肝细胞癌患者经动脉化疗栓塞术后晚期进展方面,预测性能高于现有分期系统,并能有效进行风险分层,识别从术后全身治疗中获益的患者。

研究设计与样本

  • 多中心回顾性研究(ResearchRegistry.com标识号researchregistry9425),纳入七家医院2008年6月至2022年12月接受经动脉化疗栓塞术的中期肝细胞癌患者2333例,分为训练集1026例、内部测试集257例和外部测试集1050例。

诊断标准与关键数值

  • CatBoost模型预测晚期进展的AUC:训练集0.97(95%CI:0.95,>0.99),内部测试集0.94(95%CI:0.92,0.97),外部测试集0.93(95%CI:0.90,0.95);晚期进展发生率:训练集8.4%(86/1026),内部测试集8.2%(21/257),外部测试集6.7%(70/1050)。

临床应用与阅片要点

  • 作者认为CatBoost模型可对中期肝细胞癌经动脉化疗栓塞术后患者进行风险分层,并识别可能从术后全身治疗中获益的高风险患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To develop and test a machine learning (ML)-based model that integrates preoperative variables for prediction of advanced-stage progression (ASP) after transarterial chemoembolization (TACE). Materials and Methods This multicenter retrospective study (ResearchRegistry.com identifier no. researchregistry9425) included patients with intermediate-stage hepatocellular carcinoma (HCC) who underwent TACE at seven hospitals from June 2008 to December 2022. Thirty-four preoperative clinical and CT imaging variables were input into six ML-based models for prediction of ASP, and model performances were compared. Furthermore, the best-performing ML model was compared with the major staging systems, and its utility in performing post-TACE therapies was assessed. The performances of the models were compared by using area under the receiver operating characteristic curve (AUC) with DeLong test. Kaplan-Meier survival curves were compared using the log-rank test. Results A total of 2333 eligible patients (mean age, 54 years ± 12 [SD]; 2051 male patients) were categorized into the training set (n = 1026), the internal test set (n = 257), and the external test set (n = 1050). ASP was found in 8.4% (86 of 1026), 8.2% (21 of 257), and 6.7% (70 of 1050) of patients in the three datasets, respectively. Among all ML models, the Categorical Gradient Boosting (CatBoost) model yielded the highest AUC: 0.97 (95% CI: 0.95, >0.99) for the training set, 0.94 (95% CI: 0.92, 0.97) for the internal test set, and 0.93 (95% CI: 0.90, 0.95) for the external test set. Furthermore, it yielded better discriminatory ability with higher concordance indexes than the five staging systems (all P < .001). The time-dependent AUC of the CatBoost model was also higher than that of the clinical staging systems at various time points (all P < .001). Moreover, post-TACE systemic therapy improved progression-free survival and overall survival for patients in the high-risk group (both P < .001) but not in the low-risk group. Conclusion The CatBoost model demonstrated higher predictive performance compared with existing staging systems in predicting ASP after TACE in patients with intermediate-stage HCC. This model effectively stratified patients by risk level and identified those who benefited from post-TACE systemic therapy. Keywords: Liver, Oncology, Transarterial Chemoembolization, Hepatocellular Carcinoma, Advanced-stage Progression, Machine Learning, Risk Differentiation ResearchRegistry.com identifier no. researchregistry9425 Supplemental material is available for this article. © RSNA, 2025 See also commentary by Rouzbahani in this issue.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Wei R, Liu Z, Ju L, et al. Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization. Radiol Imaging Cancer. 2025. PMID: 40910882. doi:10.1148/rycan.250034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。